Basilea Pharmaceutica Ltd. Logo
 
Products
 
 
Search
 

Products

 
 
 
  • Zevtera®/Mabelio® (ceftobiprole) is an intravenous antibiotic from the cephalosporin class. Ceftobiprole is currently marketed in major European and several other countries and Basilea has entered into license and distribution agreements for the drug in Europe, Latin America, China, Canada and Israel, the Middle East and North Africa (MENA) region.

  • Cresemba® (isavuconazole) is an intravenous and oral antifungal from the azole class. Basilea has entered into license and distribution agreements for isavuconazole in the U.S., Europe, China, Japan, Latin America, Canada, Russia, Turkey, Israel and the Asia-Pacific and Middle East and North Africa regions. In Europe, it is currently marketed in Germany, Italy, the United Kingdom, France, Spain, Austria and the Nordic countries.

  • Toctino® (alitretinoin) is an oral product for the treatment of chronic hand eczema from the class of retinoids. Alitretinoin was developed and brought to market by Basilea. Basilea entered into a global agreement on alitretinoin with Stiefel, a GSK company, in June 2012.

     

 
Info